{
  "source": "PA-Med-Nec-COPD-Lonhala-Yupelri.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2023 P 2151-8\nProgram Prior Authorization/Medical Necessity\nMedication Lonhala Magnair® (glycopyrrolate inhalation solution)*, Yupelri®\n(revefenacin inhalation solution)\nP&T Approval Date 9/2018, 1/2019, 7/2019, 8/2020, 11/2020, 11/2021, 11/2022, 11/2023\nEffective Date 2/1/2024\n1. Background:\nLonhala Magnair (glycopyrrolate inhalation solution)* and Yupelri (revefenacin inhalation\nsolution) are nebulized long-acting antimuscarinic (anticholinergic) agents indicated for the\nlong-term maintenance treatment of airflow obstruction in patients with chronic obstructive\npulmonary disease (COPD).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Lonhala Magnair* will be approved based on all of the following criteria:\na. Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)\n- AND-\nb. One of the following:\n1) History of failure, contraindication or intolerance to both of the following:\na) Spiriva® Handihaler® or Respimat® (tiotropium)\nb) Yupelri (revefenacin inhalation solution)\n- OR-\n2) Both of the following:\na) Patient is unable to use a metered-dose, dry powder or slow mist inhaler\n(e.g. Spiriva Respimat) to control his/her COPD due to one of the\nfollowing:\ni) Cognitive or physical impairment limiting coordination of handheld\ndevices (e.g., cognitive decline, arthritis in the hands) (Document\nimpairment)\nii) Patient is unable to generate adequate inspiratory force (e.g., peak\ninspiratory flow rate (PIFR) resistance is <60 L/min)\n- AND-\nb) History of failure, contraindication or intolerance to Yupelri (revefenacin\ninhalation solution)\n© 2023 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months\n2. Yupelri will be approved based on all of the following criteria:\na. Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)\n- AND-\nb. One of the following:\n1) History of failure, contraindication or intolerance to Spiriva Handihaler or\nRespimat (t",
    "Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)\n- AND-\nb. One of the following:\n1) History of failure, contraindication or intolerance to Spiriva Handihaler or\nRespimat (tiotropium)\n- OR-\n2) Patient is unable to use a metered-dose, dry powder or slow mist inhaler (e.g.\nSpiriva Respimat) to control his/her COPD due to one of the following:\na) Cognitive or physical impairment limiting coordination of handheld devices\n(e.g., cognitive decline, arthritis in the hands) (Document impairment)\nb) Patient is unable to generate adequate inspiratory force (e.g., peak\ninspiratory flow rate (PIFR) resistance is <60 L/min)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Lonhala Magnair* or Yupelri will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Lonhala Magnair is typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for\nChronic Obstructive Lung Disease (GOLD). 2023.\n2. Lonhala Magnair [package insert]. Marlborough, MA: Sunovian Pharmaceuticals Inc. August\n2020.\n© 2023 UnitedHealthcare Services Inc.\n2\n3. Yupelri [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2022.\n4. Ferguson GT, Goodin T, Tosiello R, et al. Long-term safety of glycopyrrolate/eFlow CS in\nmoderate-to-very severe COPD: result",
    "pelri [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2022.\n4. Ferguson GT, Goodin T, Tosiello R, et al. Long-term safety of glycopyrrolate/eFlow CS in\nmoderate-to-very severe COPD: results from the glycopyrrolate for obstructive lung disease via\nelectronic nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine 132; 2017:251-60.\n5. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-\nacting beta2-agonists in patients with COPD: An expert panel consensus. Chronic Obstr Pulm\nDis 2017; 4(1): 7-20\nProgram Prior Authorization/Medical Necessity – Lonhala Magnair, Yupelri\nChange Control\nDate Change\n9/2018 New program\n1/2019 Added Yupelri to the criteria.\n7/2019 Removed ipratropium as a step 1 option, added Yupelri as step 1 option\nprior to Lonhala Magnair and noted that Lonhala Magnair is typically\nexcluded from coverage.\n8/2020 Annual review. Updated references and removed step through Seebri\nNeohaler due to removal from the market.\n10/2020 Formatting update.\n11/2021 Annual review. Updated references.\n11/2022 Annual review. Removed Incruse Ellipta as a step first-line agent.\nUpdated references.\n11/2023 Annual review. Updated references.\n© 2023 UnitedHealthcare Services Inc.\n3"
  ]
}